2008 DOSE-RANGING, THREE-DAY MONOTHERAPY STUDY OF THE HCV NS3 PROTEASE INHIBITOR GS-9256

SVR was observed in naive patients 24 weeks after the completion of therapy. SVR in IL28 genotype TT patients was greater for triple therapy compared to SOC or historical controls, suggesting a potentially greater treatment effect in this high risk patient group. These data support further development of GI-5005 in combination with SOC and novel combination use with direct acting antiviral agents.